By offering deep discounts exclusively through select telehealth platforms, drugmakers create a powerful sales channel that may incentivize providers to preferentially prescribe their products. This arrangement raises ethical concerns that financial incentives could override independent medical judgment, potentially compromising patient care.
Small, pre-approval psychedelic biotechs using paid YouTube promotions with exaggerated claims risk damaging the entire field's effort to build scientific legitimacy. This marketing tactic, typically seen with consumer products, undermines attempts to attract serious investors and pharma partners by creating hype that is harmful to the sector's credibility.
Unpredictable changes in FDA review processes are more destructive to biotech investment than consistently high approval standards. Investors can adapt to a stringent but stable regulatory bar, but constant changes undermine the multi-year planning and capital commitment required for drug development, causing investors to flee.
Offering 12-month upfront subscriptions for weight-loss drugs creates a psychological 'sunk cost' for patients. This may compel them to continue using a medication despite adverse side effects or having already achieved their health goals, simply to 'get their money's worth,' potentially leading to negative health outcomes.
Individual biotech executives are reluctant to publicly challenge the FDA because their companies have drugs under active review. Forming a broad coalition with investors and patient advocates allows them to voice concerns collectively, providing a shield against potential regulatory blowback that any single company might face if it spoke out alone.
Investment firms are actively de-investing from the entire rare disease sector—not just specific companies—due to perceived FDA unpredictability. This demonstrates that capital is highly fluid and will abandon entire therapeutic areas for more stable ones, showing how sector-wide regulatory risk can starve innovation even in high-need fields.